DelveInsight’s, “B-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 160+ companies and 170+ pipeline drugs in B-Cell Lymphoma pipeline landscape. It covers the B-Cell Lymphomas pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Lymphomas pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the B-Cell Lymphomas Pipeline Report

• DelveInsight’s B-Cell Lymphomas pipeline report depicts a robust space with 160+ active players working to develop 170+ pipeline therapies for B-Cell Lymphomas treatment.
• The leading companies working in the B-Cell Lymphomas Market include Oncternal Therapeutics Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company Ltd, TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and others.
• Promising B-Cell Lymphomas Pipeline Therapies in the various stages of development include Epcoritamab, Cyclophosphamide, Rituximab, Lenalidomide, Maplirpacept (PF-07901801), Glofitamab, Obinutuzumab, and others.
• December 2023: Genmab announced a study of Phase 2 clinical trials for Epcoritamab and Lenalidomide. The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.
• December 2023: AbbVie announced a study of Phase 3 clinical trials for Epcoritamab, Cyclophosphamide, Rituximab and Vincristine. A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).

 

Request a sample and discover the recent advances in B-Cell Lymphomas Treatment Drugs @ B-Cell Lymphomas Pipeline Outlook Report

 

In the B-Cell Lymphomas pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, B-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

B-Cell Lymphomas Overview

B-cell lymphoma is a type of non-Hodgkin lymphoma that originates in the B-cells. It is the most common type of lymphoma and about 85% of all lymphomas in the United States are B-cell. Common symptoms associated with lymphoma include painless enlargement of one or more lymph node areas, fever, night sweats, and weight loss. Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma.

 

Find out more about B-Cell Lymphomas Treatment Landscape @ Drugs for B-Cell Lymphomas Treatment

 

B-Cell Lymphomas Emerging Drugs Profile

• Odronextamab: ZAI Lab
• NKTR-255: Nektar Therapeutics
• Zilovertamab Vedotin: Merck Sharp & Dohme LLC
• Abexinostat: Xynomic Pharmaceuticals

 

B-Cell Lymphomas Pipeline Therapeutics Assessment

There are approx. 160+ key companies which are developing the B-Cell Lymphomas therapies. The B-Cell Lymphomas companies which have their B-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include, ZAI Lab.

 

DelveInsight’s B-Cell Lymphomas Pipeline report covers around 170+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

 

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Learn more about the emerging B-Cell Lymphomas Pipeline Therapies @ B-Cell Lymphomas Clinical Trials Assessment

 

Scope of the B-Cell Lymphomas Pipeline Report

• Coverage- Global
• B-Cell Lymphomas Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• B-Cell Lymphomas Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• B-Cell Lymphomas Companies- Oncternal Therapeutics Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company Ltd, TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and others.
• B-Cell Lymphomas Pipeline Therapies- Epcoritamab, Cyclophosphamide, Rituximab, Lenalidomide, Maplirpacept (PF-07901801), Glofitamab, Obinutuzumab, and others.

 

Dive deep into rich insights for new drugs for B-Cell Lymphomas Treatment, Visit @ B-Cell Lymphomas Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. B-Cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. B-Cell Lymphoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Odronextamab: ZAI Lab
9. Drug profiles in the detailed report…..
10. Mid-Stage Products (Phase II)
11. Abexinostat: Xynomic Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. TG 1801: TG Therapeutics Inc.
15. Drug profiles in the detailed report…..
16. Inactive Products
17. B-Cell Lymphoma Key Companies
18. B-Cell Lymphoma Key Products
19. B-Cell Lymphoma- Unmet Needs
20. B-Cell Lymphoma- Market Drivers and Barriers
21. B-Cell Lymphoma- Future Perspectives and Conclusion
22. B-Cell Lymphoma Analyst Views
23. B-Cell Lymphoma Key Companies
24. Appendix

 

For further information on the B-Cell Lymphomas Pipeline Therapeutics, reach out @ B-Cell Lymphomas Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market